top of page

HekaBio Completes Financing Round

HekaBio K.K. announced today that it has successfully completed a financing round of JPY 400 million. Proceeds will be used to strengthen and expand HekaBio’s portfolio of innovations in development in Japan.

HekaBio specializes in the development and commercialization of innovative therapies originating from overseas, with an initial focus on cancer, fibrotic disease and autoimmune/inflammatory disorders.

Our veteran team leverages its experience and global network developed at two earlier ventures—Junicon K.K., a global medical market research-based consultancy established in Tokyo in 1992, and Vorpal Technologies K.K., a pharmaceutical and medical device CRO established in Tokyo in 2013.

HekaBio K.K. will continue its portfolio expansion and product development based on the company mission to address the unmet needs of patients and medical professionals in Japan.

About HekaBio K.K.

HekaBio’s mission is to connect world-leading healthcare innovations to unmet medical needs in Japan, with broad category development expertise in pharma, medical device, in vitro diagnostics, digital health, and cell & gene therapies. HekaBio targets innovations in oncology, fibrotic disease and autoimmune/inflammation that have a high potential for significant therapeutic benefit and healthcare cost savings.

For more information, visit

Contact: Mari Tanaka

TEL: 81-3-6205-7585



Alpha Tau Medical社、再発頭頸部癌に対するAlpha DaRTの製造販売承認申請を医薬品医療機器総合機構へ提出

参考資料 本資料は、2023年11月20日にAlpha Tau Medical社(イスラエル)が発表した英語版プレスリリースの翻訳であり、参考資料として提供するものです。正式言語は英語のため、表現や内容は英文が優先されることにご留意ください。 【イスラエル、エルサレム - 2023年11月20日】 アルファ粒子線による革新的な治療機器Alpha DaRT™の開発元であるAlpha Tau Medi


bottom of page